Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclon-Asc observational study of deep molecular response and CTL clonality in chronic phase CML treated with asciminib
jRCT1070250023Recruiting
- Sponsor
- Tatsuro Jo
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Tatsuro Jo. Primary endpoints: Changes in molecular response during asciminib treatment and Acquisition and transition of memory cytotoxic T lymphocytes during asciminib treatment. Started May 2025; status: recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT1070250023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1070250023.